Clinical trial · Observational
A Registry for Patients With Multifocal Ground Glass Opacities (GGOs)
Thoracic Surgery Oncology Group (TSOG) Protocol: Registry Trial of Active Surveillance for Multifocal Ground Glass Opacities (GGOs)
NCT03802981CI-TRIAL-00103575active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this registry study is to actively monitor people with GGOs and collect information about them, so that investigators can learn more about these lesions and about the risk of developing lung cancer in study participants whose GGOs are being monitored in the active surveillance program.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Ground Glass Opacities (GGOs) | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- lung cancer-specific survival
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Age greater than 18 years * Have two or more GGOs on initial CT imaging * GGOs must be measure ≤3.0 cm and ≥0.6 cm in the greatest dimension * GGOs must be greater than half ground glass A biopsy is not necessary for inclusion in the trial. Biopsy of a GGO, even with a diagnosis of adenocarcinoma, does not necessarily preclude enrollment in this surveillance protocol. In other words, patients with a diagnosis of adenocarcinoma are still eligible, at the discretion of the clinician and/or investigator, if they meet the above criteria. Exclusion Criteria: * Patients who are actively undergoing lung cancer treatment or have a history of lung cancer, except for cases of completely resected pathologic stage IA nonsmall cell lung cancer (NSCLC). Patients with stage IA NSCLC and multiple GGOs can enroll in this active surveillance protocol after complete resection of the NSCLC and confirmation of stage on final pathologic assessment. * The presence of any solid lesion ≥0.6 cm suspicious for malignancy. * Patients who are actively undergoing treatment for other malignancies
References
Publications (1)
- DERIVEDHuang J, Tan KS, Altorki N, Antonoff M, Blackmon S, Bueno R, Burt B, Demmy T, Evans N, Donahoe L, Harpole D, Jarrar D, Kozower B, Lanuti M, Liberman M, Lin J, Liou D, Liptay M, Luketich J, Pennathur A, Petersen G, Ripley R, Rochefort M, Seder CW, Shrager J, Su S, Tong B, Shargall Y, Vaporciyan A, Waddell T, Weksler B, Wigle D, Yendamuri S, Jones DR. Initial patient characteristics of Thoracic Surgical Oncology Group 102: A multicenter prospective registry of active surveillance in patients with multiple ground-glass opacities. J Thorac Cardiovasc Surg. 2025 Apr;169(4):1100-1107. doi: 10.1016/j.jtcvs.2024.09.054. Epub 2024 Oct 10. PMID 39395785